Peter Wirth
Chairman chez SYROS PHARMACEUTICALS, INC.
Fortune : 6 M $ au 31/03/2024
Profil
Peter Karl Wirth was the founder of Lysosomal Therapeutics, Inc. (founded in 2011) where he served as President & Director from 2011 to 2014.
He is currently the Chairman at FORMA Therapeutics, Inc., Syros Pharmaceuticals, Inc., and Centrexion Therapeutics Corp.
He is also an Independent Director at Zai Lab Ltd.
and a Venture Partner at Quan Capital Management (US) LLC.
Previously, he was the Chairman at Forma Therapeutics Holdings, Inc. from 2012 to 2022 and Executive Chairman at ZappRx, Inc. from 2016 to 2018.
He has also held positions as a Director at EPIX Pharmaceuticals, Inc., Aura Biosciences, Inc., and Synageva BioPharma Corp.
Prior to his current and former roles, he worked at Genzyme Corp.
from 1996 to 2011, holding the position of Secretary, Chief Risk Officer & Executive VP-Legal from 2009 to 2011.
He also worked at Palmer & Dodge LLP as the Head-Technology Group & Partner.
Mr. Wirth obtained his undergraduate degree from the University of Wisconsin in 1972 and his graduate degree from Harvard Law School in 1975.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ZAI LAB LTD.
0,36% | 30/06/2023 | 3 616 660 ( 0,36% ) | 6 M $ | 31/03/2024 |
| 01/06/2023 | 4 800 ( 0,02% ) | 25 680 $ | 31/03/2024 |
Postes actifs de Peter Wirth
| Sociétés | Poste | Début |
|---|---|---|
| SYROS PHARMACEUTICALS, INC. | Chairman | 30/01/2017 |
| ZAI LAB LIMITED | Director/Board Member | 01/01/2017 |
| CENTREXION THERAPEUTICS CORPORATION | Director/Board Member | - |
FORMA Therapeutics, Inc.
 FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | Chairman | - |
| Quan Capital Management (US) LLC | Corporate Officer/Principal | - |
Anciens postes connus de Peter Wirth
| Sociétés | Poste | Fin |
|---|---|---|
| FORMA THERAPEUTICS HOLDINGS, INC. | Chairman | 14/10/2022 |
ZappRx, Inc.
 ZappRx, Inc. Miscellaneous Commercial ServicesCommercial Services ZappRx, Inc. develops prescription and prior authorization platform services. It provides healthcare providers, specialty pharmacies, biopharmacies, and security standards solutions. The company was founded by Zoe Barry in 2012 and is headquartered in Boston, MA. | Chairman | 01/05/2018 |
| AURA BIOSCIENCES, INC. | Director/Board Member | 01/12/2017 |
| SYNAGEVA BIOPHARMA CORP | Director/Board Member | 22/06/2015 |
| ░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
Formation de Peter Wirth
| University of Wisconsin | Undergraduate Degree |
| Harvard Law School | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| AURA BIOSCIENCES, INC. | Health Technology |
| SYROS PHARMACEUTICALS, INC. | Health Technology |
| ZAI LAB LIMITED | Health Technology |
| Entreprise privées | 10 |
|---|---|
EPIX Pharmaceuticals, Inc.
 EPIX Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology EPIX Pharmaceuticals, Inc. used to develop targeted contrast agents both to improve the capability and expand the use of magnetic resonance imaging (MRI) as a tool for diagnosing human disease. The company was founded in 1988 and was headquartered in Lexington, MA. | Health Technology |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
FORMA Therapeutics, Inc.
FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | Health Technology |
Forma Therapeutics Holdings, Inc.
 Forma Therapeutics Holdings, Inc. Pharmaceuticals: MajorHealth Technology Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. engages in the research, development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA. | Health Technology |
Centrexion Therapeutics Corp.
 Centrexion Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Centrexion Therapeutics Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, developing, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of chronic pain. Its product pipeline includes CNTX-4975, CNTX-0290, CNTX-6970, CNTX-2022, CNTX-6016, and intrathecal platform. The company was founded by Sol J. Barer and Jeffrey B. Kindler in February 2013 and is headquartered in Boston, MA. | Health Technology |
| Palmer & Dodge LLP | Commercial Services |
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
ZappRx, Inc.
ZappRx, Inc. Miscellaneous Commercial ServicesCommercial Services ZappRx, Inc. develops prescription and prior authorization platform services. It provides healthcare providers, specialty pharmacies, biopharmacies, and security standards solutions. The company was founded by Zoe Barry in 2012 and is headquartered in Boston, MA. | Commercial Services |
Lysosomal Therapeutics, Inc.
 Lysosomal Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lysosomal Therapeutics, Inc. engages in the innovation, research, and development in the field of neurodegeneration. It focuses in lysosomal biology in developing novel small molecules for use in the treatment of neurodegenerative diseases. The company was founded by Dimitri Krainc, Joseph Mazzulli, Henri A. Termeer, Robert J. Carpenter, Peter Wirth, Edmund J. Sybertz, and Kees Cornelis Been in 2011 and is headquartered in Cambridge, MA. | Health Technology |
| Quan Capital Management (US) LLC |
